| Literature DB >> 29614136 |
April W Armstrong1, Kenneth B Gordon2, M Alan Menter3, Jashin J Wu4.
Abstract
The process of discovering new drugs for plaque psoriasis has revealed much about the multisystemic nature of the disease. Current and emerging biologic agents may reliably achieve a Psoriasis Area and Severity Index (PASI 75) up to 90. Initially, clinicians select therapies based on the severity of the psoriasis. Although mild disease can be treated with topical agents, for patients with moderate to severe disease, concurrent therapy with oral systemic agents, biologics, and/ or phototherapy needs to be considered. In some instances, clinicians may need to combine medications to provide patients with rapid relief of symptoms. Semin Cutan Med Surg 37(supp2):S39-S43. 2018 published by Frontline Medical Communications.Entities:
Keywords: Biologics; phototherapy; psoriasis pathophysiology; systemic oral therapy; topical therapy
Mesh:
Substances:
Year: 2018 PMID: 29614136 DOI: 10.12788/j.sder.2018.009
Source DB: PubMed Journal: Semin Cutan Med Surg ISSN: 1085-5629